CN107076757A - 基于RGMa片段的诊断测定 - Google Patents

基于RGMa片段的诊断测定 Download PDF

Info

Publication number
CN107076757A
CN107076757A CN201580048412.5A CN201580048412A CN107076757A CN 107076757 A CN107076757 A CN 107076757A CN 201580048412 A CN201580048412 A CN 201580048412A CN 107076757 A CN107076757 A CN 107076757A
Authority
CN
China
Prior art keywords
rgma
level
fragments
sample
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580048412.5A
Other languages
English (en)
Chinese (zh)
Inventor
S.巴霍恩
B.K.米勒
M.施米德特
A.斯特里宾格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Deutschland GmbH and Co KG
Original Assignee
AbbVie Deutschland GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Deutschland GmbH and Co KG filed Critical AbbVie Deutschland GmbH and Co KG
Priority to CN202110521844.0A priority Critical patent/CN113267630A/zh
Publication of CN107076757A publication Critical patent/CN107076757A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
CN201580048412.5A 2014-09-10 2015-09-09 基于RGMa片段的诊断测定 Pending CN107076757A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110521844.0A CN113267630A (zh) 2014-09-10 2015-09-09 基于RGMa片段的诊断测定

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462048745P 2014-09-10 2014-09-10
US62/048745 2014-09-10
PCT/EP2015/070603 WO2016038084A1 (en) 2014-09-10 2015-09-09 Rgma fragment based diagnostic assay

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110521844.0A Division CN113267630A (zh) 2014-09-10 2015-09-09 基于RGMa片段的诊断测定

Publications (1)

Publication Number Publication Date
CN107076757A true CN107076757A (zh) 2017-08-18

Family

ID=54064367

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580048412.5A Pending CN107076757A (zh) 2014-09-10 2015-09-09 基于RGMa片段的诊断测定
CN202110521844.0A Pending CN113267630A (zh) 2014-09-10 2015-09-09 基于RGMa片段的诊断测定

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110521844.0A Pending CN113267630A (zh) 2014-09-10 2015-09-09 基于RGMa片段的诊断测定

Country Status (10)

Country Link
US (3) US20160069907A1 (enExample)
EP (1) EP3191847A1 (enExample)
JP (1) JP6879905B2 (enExample)
CN (2) CN107076757A (enExample)
AU (2) AU2015314240A1 (enExample)
BR (1) BR112017004883A2 (enExample)
CA (1) CA2956814A1 (enExample)
MX (2) MX385216B (enExample)
TW (2) TW202119030A (enExample)
WO (1) WO2016038084A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2632476A1 (en) * 2005-12-05 2007-06-14 Affinium Pharmaceuticals, Inc. Heterocyclylacrylamide compounds as fabi inhibitors and antibacterial agents
MX2012006560A (es) * 2009-12-08 2012-10-05 Abbott Gmbh & Co Kg Anticuerpos monoclonales contra la proteina rgm a para utilizarse en el tratamiento de degeneracion de capa de fibra de nervio retinal.
CN116942831A (zh) 2018-07-19 2023-10-27 国立大学法人东京大学 Htlv-1相关性脊髓病（ham）治疗或预防剂、及ham的治疗方法
CN118767130A (zh) * 2020-01-15 2024-10-15 国立大学法人大阪大学 糖尿病性自主神经障碍的预防或治疗剂
CN112402554B (zh) * 2020-10-26 2022-03-01 中国中医科学院广安门医院 一种治疗脑白质病的中药组合物及其应用
US12306192B2 (en) 2021-02-08 2025-05-20 Cedars-Sinai Medical Center Method of detecting cognitive impairment
EP4374300A4 (en) * 2021-07-23 2025-06-11 Cedars-Sinai Medical Center Methods and systems for the early detection of ocular and/or neurological conditions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102656190A (zh) * 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
CN102811739A (zh) * 2009-12-09 2012-12-05 田边三菱制药株式会社 T细胞活化抑制剂、含有其的药物组合物以及抑制t细胞活化的物质的筛选方法
US20140023659A1 (en) * 2012-01-27 2014-01-23 Abbvie Inc. Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002053A2 (en) * 1998-07-03 2000-01-13 Innogenetics N.V. Differential diagnosis of neurodegeneration
EP1355666B1 (en) 2000-12-22 2012-06-13 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Use of repulsive guidance molecule (RGM) and its modulators
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP3252072A3 (en) * 2010-08-03 2018-03-14 AbbVie Inc. Dual variable domain immunoglobulins and uses thereof
WO2012047706A2 (en) * 2010-10-06 2012-04-12 Massachusetts Eye & Ear Infirmary Methods for promotiing reinnervation of auditory hair cells
EP2723866B1 (en) * 2011-06-22 2018-03-28 Universite Laval Methods for the prognostic and/or diagnostic of neurodegenerative disease, methods to identify candidate compounds and compounds for treating neurodegenerative disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102656190A (zh) * 2009-12-08 2012-09-05 雅培股份有限两合公司 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体
CN102811739A (zh) * 2009-12-09 2012-12-05 田边三菱制药株式会社 T细胞活化抑制剂、含有其的药物组合物以及抑制t细胞活化的物质的筛选方法
US20140023659A1 (en) * 2012-01-27 2014-01-23 Abbvie Inc. Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KATSUHIKO HATA ET AL: "RGMa inhibition promotes axonal growth and recovery after spinal cord injury", 《JCB》 *
NARDOS G. TASSEW ET AL: "SKI-1 and Furin Generate Multiple RGMa Fragments that Regulate Axonal Growth", 《DEVELOPMENTAL CELL》 *
RIEKO MURAMATSU ET AL: "RGMa modulates T cell responses and is involved in autoimmune encephalomyelitis", 《NATURE MEDICINE》 *

Also Published As

Publication number Publication date
BR112017004883A2 (pt) 2017-12-05
AU2022200160A1 (en) 2022-02-10
US20160069907A1 (en) 2016-03-10
EP3191847A1 (en) 2017-07-19
US20220018855A1 (en) 2022-01-20
WO2016038084A1 (en) 2016-03-17
TW202119030A (zh) 2021-05-16
CA2956814A1 (en) 2016-03-17
US20200241012A1 (en) 2020-07-30
AU2015314240A1 (en) 2017-02-09
CN113267630A (zh) 2021-08-17
MX2021009528A (es) 2021-09-08
JP6879905B2 (ja) 2021-06-02
JP2017526930A (ja) 2017-09-14
MX385216B (es) 2025-03-14
MX2017003063A (es) 2017-06-14
TW201617612A (zh) 2016-05-16

Similar Documents

Publication Publication Date Title
US20220018855A1 (en) RGMa Fragment Based Diagnostic Assay
CA2897336C (en) Evaluation and treatment of pkal-mediated disorders
JP2011509676A (ja) ヒトＴｈ１７細胞の選択的分化、同定および調節
EP3254106A1 (en) Methods and compositions for diagnosing brain injury or neurodegeneration
WO2011094535A2 (en) Biomarkers of aging for detection and treatment of disorders
US20220057409A1 (en) Combinatorial temporal biomarkers and precision medicines with detection and treatment methods for use in neuro injury, neuro disease, and neuro repair
CA2745189A1 (en) Methods for detection of sepsis
KR20200112906A (ko) 척추 근위축증의 치료 방법
EP2619583B1 (en) Diagnostic method for bacterial meningitis
US20240317876A1 (en) Treatment Of Multiple Sclerosis And Neuromyelitis Optica
MX2014004319A (es) Valoracion del riesgo de pml (leucoencefalopatia multifocal progresiva) y metodos basados en la misma.
US7709215B2 (en) Method for diagnosing and treating acute joint injury
WO2017176385A1 (en) Compositions and methods for diagnosing and treating brain injury
WO2006138219A2 (en) Methods of diagnosis / prognosis of inflammatory conditions
US20230190967A1 (en) Method and Composition for Evaluating Response to Neurodegenerative Disease Treatment Agent
US20210215692A1 (en) Compositions and methods for treating inflammatory diseases
US20140377883A1 (en) Peripherin-specific autoantibodies as a marker for neurological and endocrinological disease
신수진 Integrative Biomarker Discovery in Cryptogenic New-Onset Refractory Status Epilepticus
WO2026039731A1 (en) Antibody genetics of radiologically isolated syndrome

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20170818